Swedish Orphan Biovitrum (OTCMKTS:BIOVF) Shares Gap Up – What’s Next?

Swedish Orphan Biovitrum (OTCMKTS:BIOVF)’s stock price gapped up before the market opened on Monday . The stock had previously closed at $41.32, but opened at $43.15. Swedish Orphan Biovitrum shares last traded at $43.15, with a volume of 100 shares traded.

Analyst Ratings Changes

BIOVF has been the subject of a number of research reports. Barclays reiterated an “overweight” rating on shares of Swedish Orphan Biovitrum in a research report on Tuesday, February 24th. Danske lowered shares of Swedish Orphan Biovitrum to a “hold” rating in a research report on Thursday, February 19th. Finally, BNP Paribas Exane upgraded shares of Swedish Orphan Biovitrum to an “outperform” rating in a research report on Tuesday, February 10th. Three research analysts have rated the stock with a Buy rating and one has assigned a Hold rating to the stock. According to MarketBeat, the company presently has an average rating of “Moderate Buy”.

Swedish Orphan Biovitrum Price Performance

The business’s 50-day moving average price is $40.10 and its 200 day moving average price is $37.04. The company has a quick ratio of 0.59, a current ratio of 0.90 and a debt-to-equity ratio of 0.14. The company has a market capitalization of $15.36 billion, a P/E ratio of 331.95 and a beta of 0.35.

Swedish Orphan Biovitrum (OTCMKTS:BIOVF) last released its quarterly earnings data on Thursday, February 5th. The company reported $0.60 EPS for the quarter, beating analysts’ consensus estimates of $0.46 by $0.14. Swedish Orphan Biovitrum had a net margin of 1.43% and a return on equity of 15.74%. The company had revenue of $846.23 million during the quarter, compared to analyst estimates of $879.40 million.

Swedish Orphan Biovitrum Company Profile

Swedish Orphan Biovitrum AB (publ), commonly known as Sobi, is a Stockholm?based biopharmaceutical company specializing in the development, manufacturing and commercialization of treatments for rare diseases. Formed in 2010 through the merger of Swedish Orphan International AB (established 1985) and Biovitrum AB, the company focuses on high?value therapies in hematology, immunology, oncology and genetic/metabolic disorders. Sobi’s strategy centers on building a global specialty care portfolio by in?licensing, acquiring and internally developing innovative products aimed at small patient populations with significant unmet needs.

The company’s marketed portfolio includes recombinant clotting factor therapies such as Elocta (rFVIIIFc) and Alprolix (rFIXFc) for hemophilia A and B, respectively; Ruconest, a recombinant human C1 esterase inhibitor for hereditary angioedema; and Kineret (anakinra) for certain auto?inflammatory conditions.